Actionable insights straight to your inbox

Equities logo

After Merck Stops Study, What Remains Of The Alzheimer’s Drug Pipeline?

?This is a re-post of a great article by Taylor Cox , Benzinga Staff Writer ?brought to our attention by one of our shareholders
We now live in the age of angels—business angels, that is, where every day more and more affluent individuals are providing needed capital for small and medium-sized enterprises (SMEs) and